Thursday, 12th November Clinical Oncology Society of Australia Annual Scientific Meeting 2020

7:15AM - 8:45AM
Thursday, 12th November
Stream C
Chair: Meera Agar
Co-chair: Darshit Thaker
Sponsored by:

This session will introduce the concept of geriatric oncology assessment and management, how to implement various assessment tools successfully to formally assess older patients before planning for oncological therapy and discussion on recent research outcomes and further research potential in the field of Geriatric Oncology.

Chairs: Dr Meera Agar & Dr Darshit Thaker

Dr Wee-Kheng Soo, Geriatric Oncologist, Eastern Health VIC
Dr Christopher Steer, Medical Oncologist, Border Medical Oncology NSW
Dr Darshit Thaker, Consultant Medical Oncologist & Palliative Medicine Physician, Royal Brisbane & Women's Hospital QLD
Dr Heather Lane, Geriatrician, Rockingham General Hospital WA
Dr Penny Mackenzie, Radiation Oncologist, St Andrew's Hospital, Toowoomba QLD, Icon Cancer Centre
Bernadette Kelly, Senior Occupational Therapist, Cancer Care Services, Redcliffe Hospital QLD
Stella Snape-Jenkins, Senior Occupational Therapist, Oncology Services, Caboolture Hospital QLD
Hermione Wheatley, Geriatric Oncology CN, NLCCS, Royal Brisbane & Women's Hospital QLD

This symposium has been donated to COSA from AstraZeneca. AstraZeneca had no influence on the symposium organisation, subject or content.

7:15AM - 8:45AM
Thursday, 12th November
Stream A
Sponsored by:

Description: Lilly kindly invites you to join our symposium to learn from Consultant Medical Oncologist Dr Mark Verrill (UK) & Clinical Nurse Specialist Karen Verrill (UK) on how they manage their complex MBC patients with poor prognostic factors, and what influences their CDK4&6 inhibitor prescribing decisions.

Chairs: Dr Rohit Joshi, Consultant Medical Oncologist, Director Cancer Research Adelaide Oncology & Haematology, Calvary Central Districts & North Adelaide Hospitals

Dr Mark Verrill, Consultant Medial Oncologist, Head of the Department of Medical Oncology and the deputy lead clinician for breast cancer in the North of England Cancer Network Karen Verrill, Clinical Nurse Specialist | Northern Centre for Cancer Care (NCCC) | Centre Head at Maggie's Centres
Fran Boyle, Medical Oncologist at North Sydney’s Mater Hospital, Director of the Patricia Ritchie Centre for Cancer Care and Research, Professor of Medical Oncology at the University of Sydney.

This morning symposium is sponsored by Eli Lilly

7:30AM - 8:45AM
Thursday, 12th November
Stream B
Sponsored by:

Description: Neuroendocrine neoplasms (NEN) are rare tumors that are highly heterogeneous with regards to their origin, responses to therapies and ultimately prognosis. Owing to this heterogeneity and the consequent complexity of NEN management, a mutil-disciplinary approach is advised for the effective management of Neuroendocrine neoplasms to facilitate optimal patient outcomes.

This educational symposium will review the current best practice in the management of NENs. It will consider both current therapeutic approaches in Medical Oncology and Nuclear Medicine as well as discussing how inclusion of other disciplines such as Nutrition in to a collaborative Multi-Discplinary Team can help to optimise patient outcomes.

Chair: David Chan, Medical Oncologist, Royal North Shore Hospital, NSW

David Chan, Medical Oncologist, Royal North Shore Hospital, NSW
Grace Kong, Nuclear Medicine Physician, Peter MacCallum Cancer Institute, Victoria, Australia
Erin Laing, Oncology Dietician, Peter MacCallum Cancer Institute, Victoria, Australia

This morning symposium is sponsored by Ipsen


10:30AM - 10:45AM
Thursday, 12th November
1:00PM - 1:30PM
Thursday, 12th November
1:30PM - 1:50PM
Thursday, 12th November
Stream A
Chair: Nick Pavlakis
1:50PM - 2:30PM
Thursday, 12th November
Stream A
Chair: Jeremy Long
Co-chair: Cassandra Dickens
Sponsored by:

You saw how QOOL can help with ‘big data’, but now, here’s a session to demonstrate the real power for individual patients and their treating teams. By optimising data availability at the point of contact, learn about how QOOL can assist both you and your patient throughout the cancer care trajectory.

QOOL is an initiative of Cancer Alliance Queensland to support Queensland’s progress in delivering safe quality cancer care.  Significant improvements in cancer care have been achieved since the introduction of QOOL in 2009.  Data and clinical scenarios from QOOL will be explored in further detail in each of the presentations.

QOOL is a web-based, customisable system which supports cancer multidisciplinary teams by assisting meeting preparation, communication and documentation of essential clinical information such as diagnosis, cancer stage and recommended treatment plans. QOOL provides a centralised platform of patient data for multiple users, accessible anywhere, anytime. As a multisided platform QOOL connects clinicians to patient data drawn from 60 clinical and administrative systems. Imagine having real time data at your fingertips which allows you to manage patients, communicate with colleagues, conduct audits, participate in research and gain insights into your local practice.

The plenary will comprise 4 oral presentations showcasing various aspects of the QOOL platform: the first one will review QOOL in Action, next we showcase a statewide Myeloid MDT highlighting the benefits of collecting structured data and providing a real-world example of recording consumable genomics information; then we show you how to BYO (build your own) QOOL project; and finally we have Tracking your multidisciplinary meeting performance using QOOL-Dash.

The papers will be followed by a panel discussion where you can draw on the presenters’ firsthand experience of utilising a purpose built clinical cancer application to improve care for your patients locally.

1:50 PM Jeremy Long
Live QOOL MDT in action! 

1:56 PM Kirk Morris
Bridging the geographic divide for myeloid leukaemia – a statewide system accessible to everyone  

2:04 PM Benjamin Chua
Build your own QOOL Project

2:12 PM Bryan Chan
QOOL dash - Tracking my Lung cancer MDT performance

2:20 PM Panel Discussion 

3:45PM - 4:00PM
Thursday, 12th November
4:00PM - 5:30PM
Thursday, 12th November
Stream C
Chair: Cassandra Dickens
Co-chair: Curtis Forbes
Sponsored by:

5:15 PM Panel Discussion 

6:00PM - 7:30PM
Thursday, 12th November
Stream A
Chair: Ken O'Byrne
Sponsored by:

The introduction of immunotherapies has no doubt lead to greater efficacy outcomes for cancer patients across a broad range of tumour types. With these benefits, however, can come a range of immune related Adverse Reactions (irARs) that if not treated early and appropriately may have serious implications for the patient. To optimise management of patients on Immuno-Oncology (IO) treatments, patients need to be empowered to understand their treatment and to recognise and report adverse reactions or irARs early to their care team. It is also important that specialists involved in the management of patients experiencing an irAR are cognisant of the unique management required to ensure optimal patient outcomes. In this educational symposium we will explore:
- Best practice on empowering patients to be active in identifying and reporting any irARs
- How forming a collaborative cross-specialist network to treat irARs can help to optimise patient outcomes.

Professor Kenneth O’Byrne, consultant and professor of Medical Oncology and Clinical Scientist, Princess Alexandra Hospital (PAH) and Queensland University of Technology (QUT) Translational Research Institute (TRI) Laboratories
A/Prof Alex Menzies, Medical Oncologist, Melanoma Institute Australia

Dr Lavinia Spain, Peter MacCallum Cancer Centre, Medical Oncologist
Dr Megan Lyle, Cairns Private Hospital, Medical Oncologist
Dr Rob Zielinski, Orange Base Hospital, Medical Oncologist
A/Prof Victoria Atkinson, Princess Alexandra Hospital, Medical Oncologist 
Rebecca Kimberley, Princess Alexandra Hospital, Clinical Nurse Consultant Lung Cancer

This evening symposium is sponsored by Bristol Myers Squibb.